Crispr gene-editing breakthrough is a big deal. How big?
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Tuesday
February 07, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
TUESDAY, FEBRUARY 07, 2023
Crispr gene-editing breakthrough is a big deal. How big?

Panorama

Sam Fazeli, Bloomberg
30 June, 2021, 12:25 pm
Last modified: 30 June, 2021, 12:30 pm

Related News

  • Cirrhosis of the Liver: Symptoms, Causes, Stages & Prevention
  • Experimental synthetic cornea restores vision for 20 patients
  • Monkeypox virus could become entrenched as new STD in the US
  • Afghan health official warns of disease outbreak among earthquake survivors
  • Nepal reports first African swine fever outbreak, OIE says

Crispr gene-editing breakthrough is a big deal. How big?

For the first time, gene-modifying technology was shown to work in the human body to treat disease, offering huge hope for further uses. Here’s what you need to know

Sam Fazeli, Bloomberg
30 June, 2021, 12:25 pm
Last modified: 30 June, 2021, 12:30 pm
The era of curing disease by tweaking DNA just got a lot closer. Photo: Bloomberg 
The era of curing disease by tweaking DNA just got a lot closer. Photo: Bloomberg 

Sam Fazeli, a Bloomberg Opinion contributor who covers the pharmaceutical industry for Bloomberg Intelligence, answers questions after Intellia Therapeutics Inc. and Regeneron Pharmaceuticals Inc. released promising findings from the first human clinical trial using gene-editing Crispr technology in the body to treat a disease. Intellia shares surged more than 40% on the news. The conversation has been edited and condensed.

This is the first successful in-human gene editing with Crispr that we know of, and it seems to work really well. Is this a big deal?

The answer is an emphatic yes. This new data, even though from just a handful of patients, shows not only that this new technology works in humans, but that it is also very safe, at least at the two doses that were tested in this trial. It's important because it's the first time that scientists have been able to modify DNA in a patient's cells in a very specific way. This fascinating technology, very simply, is a molecular scissors (Cas9) that is led by a "guide RNA" to cut a specific part of DNA. Bacteria use this method to inactivate invading viruses. In Intellia's trial, the system is used to deactivate the gene for a misfolded protein known as transthyretin, or TTR, which can build up in patients in some rare cases, leading to neurological and heart damage that is eventually fatal.

Why might it work better than other forms of genetic therapy that are already approved?

The beauty of what Intellia has done is that it has produced a highly specific "knockdown" of one disease gene, though more data is needed to prove that is 100% specific in humans. The other way that people have been tackling this type of disease involves either using antibodies targeted against a protein or some form of RNA-silencing or anti-sense methods, to stop the production of a protein. Indeed, there is already an approved drug from Alnylam (Onpattro) for the rare disease that Intellia is targeting. But these are drugs that need continuous therapy, whereas the gene-editing methods should be one and done.

This sort of editing is permanent -- that's probably a good thing in terms of having the desired effect on disease, but that also sounds scary. Is there any reason it might be problematic?

Not really, especially if scientists prove that it is indeed as specific as the technology is designed to be and has appeared to be so far in animal studies. But more data is needed to prove that. The problem is that the human body is very complex, and there will always be some risk that it works much better in some than others. Indeed, the data showed that the effects from the same dose varied among three different people. One good thing about the Intellia technology is that it uses lipid nanoparticles to deliver its payload -- similar to those used in the mRNA vaccines from Pfizer-BioNTech and Moderna. This reduces the risks that are associated with using viruses, which most other gene therapies use.

Are there any safety concerns?

The data showed few side effects, which was amazing. But the company is going to go to a higher dose in the next set of patients -- one that's three times higher than the highest dose tested so far. This may increase the side effects. But the technology may be good enough at cutting the problem protein at the current dosage that Intellia may not need to take that risk. There could also be an immune response to the Cas9 protein the system needs to do its job correctly. If that is the case, it is unlikely to cause a problem by itself but may make delivering a second dose problematic, which means that the effect from the first needs to stick.

Speaking of which, what about durability. Is the effect going to last?

This is a key question. In animal studies, the effect has been maintained for at least 52 weeks. But in humans, the data stops at 28 days for now. So the company needs to show that the reductions in protein levels in humans are maintained. Otherwise, as noted above, the opportunity for redosing with the same drug is likely very limited. Other companies are working on different versions of the technology that may allow for redosing, but a lot more work needs to be done to see if they're needed or that's possible.

What's the path forward for Intellia and for this sort of gene editing in general? When might it be more broadly available?

Durability and long-term safety will be important because the drug may cost hundreds of thousands of dollars or more. But Intellia also needs to show clinical benefit in the patients, though I suspect, given the direct correlation between TTR levels and disease, this is not a huge risk in this setting. On the path forward, these findings prove the feasibility of "gene knockout" in humans. Intellia has other programs using this technique to treat other diseases, including a swelling disorder called hereditary angioedema. The next step is whether scientists can literally "edit" a gene to correct a mutation. Intellia and several other gene-editing companies have such programs under way. The critical questions are: Can real gene editing be done at high efficiency in patients, and can this be done in any organ and not just those that are relatively easily accessible, such as the liver? The other issue is whether the system can be used to correct multiple mutations because not all diseases are caused by just one.

Is Crispr definitely the way forward in gene editing, or could we do even better?

There are other technologies in development, such as TALENs, Sangamo's zinc-finger nucleases, and site-specific nucleases. But in the end, they all try to achieve the same thing. Intellia's data shows that, at least in some settings where the target organ is easy to access, this can be done inside a human being. This opens the door for all these technologies to be tested. It will take additional study and in-human data to show any advantages or problems.

Gene editing comes with some ethical concerns -- how do we make sure it's used in the right way?

That's a big societal issue. We have seen it play out when it came to cloning Dolly the sheep. In the end, it is the job of science to come up with new technologies and for regulators and governments to ensure that they are applied for the right reasons, in the right way and in the right context.

You touched on the likely high cost of the drug above. Other gene therapies have been extremely expensive, with companies invoking the "one and done" aspect of these treatments as a justification. Will this follow the same path?

I think this is where we will have to have more discussion and find better ways of encouraging innovation without making treatment unaffordable. I have heard of buying clubs, for example, for Novartis's gene therapy Zolgensma for spinal muscular atrophy, a rare but devastating disease for some babies. But at a cost of about $2 million, this is extremely difficult to finance. If gene editing does eventually deliver on its promise, given the number of single-gene diseases, it could create a significant cost burden on society that is still reeling from the economic effects of the pandemic.

Sam Fazeli
Sam Fazeli

Sam Fazeli is a Pharmaceuticals analyst.

Top News

gene / disease / Crispr

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • A general view shows damaged and collapsed buildings after an earthquake in Kahramanmaras, Turkey February 6, 2023. Ihlas News Agency (IHA) via REUTERS
    Deaths exceed 4,300 as catastrophic quakes ravage Turkey, Syria
  • 30% cos see double-digit growth even in hard times
    30% cos see double-digit growth even in hard times
  • Each Reverse Osmosi plant can produce approximately 8,000 litres of drinking water a day for around 250 families. Photo: Sadiqur Rahman
    A drop in the ocean of persistent water crisis

MOST VIEWED

  • Each Reverse Osmosi plant can produce approximately 8,000 litres of drinking water a day for around 250 families. Photo: Sadiqur Rahman
    A drop in the ocean of persistent water crisis
  • Mohammad Zaved Akhtar/TBS Sketch
    Unilever CEO warns of tough 9-10 months ahead
  • Illustration: TBS
    Decoding Monetary Policy Statement 2023: Was there any better alternative?
  • Why Pakistan is struggling to get another IMF bailout
    Why Pakistan is struggling to get another IMF bailout
  • Photo: Courtesy
    From 'Made in Bangladesh' to 'Designed in Bangladesh'
  • The megaproject Rooppur Nuclear Power Plant has a debt of Tk90,474 crore. Photo: Courtesy
    Projects funded with debt need to be selected prudently, and implemented timely

Related News

  • Cirrhosis of the Liver: Symptoms, Causes, Stages & Prevention
  • Experimental synthetic cornea restores vision for 20 patients
  • Monkeypox virus could become entrenched as new STD in the US
  • Afghan health official warns of disease outbreak among earthquake survivors
  • Nepal reports first African swine fever outbreak, OIE says

Features

Nimah designed by Compass Architects- Wooden tiles. Photo: Junaid Hasan Pranto

Trendy flooring designs to upgrade any space

35m | Habitat
Benefits of having high ceilings in your new home

Benefits of having high ceilings in your new home

5m | Habitat
Each Reverse Osmosi plant can produce approximately 8,000 litres of drinking water a day for around 250 families. Photo: Sadiqur Rahman

A drop in the ocean of persistent water crisis

1h | Panorama
Photo: Collected

Get your partner a lovely present this Valentine's Day

1d | Brands

More Videos from TBS

Who will survive? Adani or Hindenburg?

Who will survive? Adani or Hindenburg?

14h | TBS Stories
James Gunn’s 8-10-year plan for the DC Universe

James Gunn’s 8-10-year plan for the DC Universe

14h | TBS Entertainment
LC issues lead to severe shortage of surgical equipment

LC issues lead to severe shortage of surgical equipment

18h | TBS Insight
Stage plays are going on in the digital age

Stage plays are going on in the digital age

22h | TBS Stories

Most Read

1
Photo: Courtesy
Panorama

From 'Made in Bangladesh' to 'Designed in Bangladesh'

2
Leepu realised his love for cars from a young age and for the last 40 years, he has transformed, designed and customised hundreds of cars. Photo: Collected
Panorama

'I am not crazy about cars anymore': Nizamuddin Awlia Leepu

3
Master plan for futuristic Chattogram city in the making
Districts

Master plan for futuristic Chattogram city in the making

4
The International Monetary Fund (IMF) logo is seen outside the headquarters building in Washington, U.S., September 4, 2018. REUTERS/Yuri Gripas/File Photo
Economy

IMF approves $4.7 billion loan for Bangladesh, calls for ambitious reforms

5
Belal Ahmed new acting chairman of SIBL
Banking

Belal Ahmed new acting chairman of SIBL

6
Photo: Collected
Crime

Prime Distribution MD Mamun arrested in fraud case

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]